Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company’s clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health’s National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Filspari's Triumph | Explore Travere Therapeutics' market resurgence following Filspari's full FDA approval for IgA nephropathy, doubling its addressable market and boosting growth prospects |
Financial Outlook | Analyst projections show revenue rebounding to $230.5M in FY 2024, with EPS estimates ranging from -$3.05 to -$0.53, reflecting ongoing challenges and potential |
Competitive Edge | Delve into Travere's strengthened position in the rare kidney disease market, with Filspari poised to become a standard of care amid evolving treatment guidelines |
Future Catalysts | Learn about Travere's growth drivers, including REMS modifications and new indications for Filspari, with analyst price targets ranging from $12 to $20 |
Metrics to compare | TVTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTVTXPeersSector | |
---|---|---|---|---|
P/E Ratio | −4.2x | −2.8x | −0.7x | |
PEG Ratio | 0.02 | 0.01 | 0.00 | |
Price/Book | −47.6x | 2.1x | 2.6x | |
Price / LTM Sales | 7.1x | 7.0x | 3.2x | |
Upside (Analyst Target) | 30.7% | 118.2% | 47.0% | |
Fair Value Upside | Unlock | 4.5% | 8.3% | Unlock |